While early identification of DKD is important (see Question 1), it iscritical to note that the interventions for cardiorenal protectionidentified in this document, including SGLT2 inhibitors and finerenone, canprovide benefits for most patients with DKD, regardless of stage. Here, SLC5A2 is linked to diabetic kidney disease.